Shots: The approval is based on the P-III VICTORIA trial involves assessing Verquvo (2.5mg, 5mg & 10mg) in patients with CHF, published in NEJM in Mar’20. The therapy is being […]readmore
Tags : Vericiguat
Shots: The NDA is based on P-III VICTORIA study assessing vericiguat (qd, (titrated up to 10mg) vs PBO when given in combination with available HF therapies in ~5,050 patients with […]readmore
Shots: The P-III VICTORIA study involves assessing of Vericiguat vs PBO in combination with available HF therapies in 5,050 patients with worsening chronic heart failure with reduced ejection fraction (HFrEF) […]readmore